Barbara Ryan

Founder and CEO of Barbara Ryan Advisors

Extensive experience as a sell-side research analyst for 30 years followed by 12 years of subsequent experience working as a virtual E-Team and Board member of a large and diverse universe of companies, especially those highly dependent on capital raising to fund development programs, growth strategies, and M&A.

  • After a 30+year career as a sell-side pharmaceutical analyst on Wall Street, founded Barbara Ryan Advisors in 2012 to offer senior strategic communications counsel, a full range of IR services, fundraising and M&A support to the C-suite of a wide range of life sciences companies.
  • Extensive experience as a sell-side research analyst combined with 12 years of subsequent experience working as a virtual E-Team and Board member of a large and diverse universe of companies, especially those highly dependent on capital raising to fund development programs, growth strategies, and M&A.
  • Deep industry insights, relationships and well-informed recommendations on best practices around corporate narratives, disclosures, guidance, financing, and M&A strategies to optimize growth and optionality. Barbara has helped raise well over $2 billion in capital across the sector.
  • Widely sought as a subject matter expert to speak on panels at leading industry events, widely quoted in the media, and a member of a number of advisory boards. I bring a wealth of expertise, strategic thinking, relationships, and advocacy to any life sciences endeavor.
  • • Passionate and vocal advocate for diversity and inclusion in the industry. Founded Fabulous Pharma Females, a non-profit dedicated to advancing women in biopharma and I have a commitment to supporting and mentoring women.

Expertise

Corporate communications & investor relations

I have extensive experience in creating and articulating compelling corporate narratives that resonate with the investment community. I have worked with biopharma leaders to develop press releases, corporate presentations, website content, and presentation scripts that effectively communicate the company's story to investors.

Capital Raising/ M&A/ Transactions

Barbara has helped raise over $2.0 billion for private and public emerging biopharma companies in IPOs, follow-ons, PIPEs and convertible debt transactions. Barbara has been engaged in multiple M&A transactions, including Shire/Abbvie hostile defense and hostile Shire/Baxalta transaction as well as multiple smaller deals. Extensive relationships across the life sciences capital markets ecosystem, including the investment community, sell-side analysts, investment bankers, lawyers, venture capital firms, P/E firms and corporate management teams.

SEC and financial reporting

I have extensive experience with SEC and financial reporting. I was responsible for analyzing biopharma company quarterly reports and SEC filings for over 30 years as an analyst, and bring extensive SEC and financial reporting experience to clients and board audit committees. Co-developed S-1s, 10Ks, 8Ks, and annual reports for public and private companies; contributed to due diligence and banker / analyst selection for IPOs, secondary equity offerings, and debt financings. Held FINRA Series 7 and 43 licenses. As a Board audit committee member of six companies, and Chair of one, I live these issues daily with a high level of responsibility and am able to keep current on accounting standards and SEC requirements.

Board experience

I am a board member at several biopharma companies, including Indivior PLC, MiNK Therapeutics, INVO Biosciences, Azitra, OcuTerra, and Safecor. This experience gives me a unique perspective on the challenges and opportunities facing biopharma companies, and it allows me to help companies problem solve and develop and execute effective strategies to achieve their objectives and drive value for all stakeholders

Therapeutics and pipelines

I have a deep understanding of biopharma therapeutics across all disease states and have analyzed and modeled pipelines across most. I have over 30 years of experience analyzing biopharma company quarterly reports and SEC filings, clinical data and commercial results. This gives me a unique understanding of the factors that drive investor interest in and valuation of portfolios and pipelines, how to communicate their value propositions as well as commercial strategies through thorough strategic communications that can drive enterprise value.

People development

I have extensive experience in people development. I have hired and trained staff, including analysts and CFOs, at major financial institutions and biotech companies. I am also a strong mentor and coach, and I have helped to develop the careers of many prominent sell-side analysts, as well as investment bankers.

Women's leadership

I am passionate about advancing the careers of women in biopharma. I instituted women's leadership development initiatives at Radius and Eloxx, and I am the founder of Fabulous Pharma Females 501(c)(3), a non-profit organization dedicated to advancing the careers of women in biopharma.

Services

IPO | Capital Raising | M&A

Investor Relations (IR)

Strategic Communications Lead / Advisor

Capital Markets Advisory

Corporate Power Point Presentations

Press Releases

Presentation scripts

Client Advisory & Marketing Strategies

Public Speaking/Coaching

Media Training

Business Development

Executive Talent Acquisition

Training, Mentoring & Leadership

Relationship Building & Networking

Expert Witness Testimony

Clients

Eloxx Pharmaceuticals – IR and Strategy
Qualigen
Zoetis
beigene
Centrexion
Agenus
RadiusLogoHorizontal
rafael_holdings
perrigo-logo
Centrexion
RadiusLogoHorizontal
marinus
Esperion
RadiusLogoHorizontal
Cardinal
ELOX
Cardinal
Syndax
rlyp_logo-1
Roivant_Sciences_Logo
Eyepoint
shire
Zoetis
Ernst Young Senior Advisor
shire
Zoetis
beigene
Cardinal
Allergan
Agenus
MiNK
rafael_holdings
perrigo-logo
Centrexion
RadiusLogoHorizontal
marinus
Esperion
Invea
ELOX
ContraFect
Syndax
rlyp_logo-1
Roivant_Sciences_Logo
Eyepoint
Qualigen
Vesselon

Boards/Advisory

2020 - Present

Ernst & Young

Senior Advisor

2021 - Present

MiNK Therapeutics

Audit Committee (Chair) and Compensation Committees

2022 - Present

Safecor Health

Audit and Compensation Committees

2020 - Present

INVO Bioscience

Audit, Compensation, Nominating and Governance, and Finance (Chair) Committees

2020 - Present

The Biopharma Hub

Faculty Member

2018 - Present

Red Door Community New York

Member, Board Of Directors

2012 - Present

The Galien Foundation

Member, Executive Advisory Board For Prix Galien

2022 - Present

Indivior PLC

Audit, Science, Remuneration and Compensation, Nominating and Compliance Committees

2021 - Present

OcuTerra Therapeutics

Audit, Finance and Transaction Committee

2023 - Present

Azitra

Audit and Compensation (Chair) Committees

2014 - Present

Springboard Enterprises

Life Sciences Council Member

2010 - 2019

Villa Maria Education Center

Chair, Board Of Trustees

2010 - Present

Fabulous Pharma Females 501 (c) (3)

FOUNDER

2008 - Present

Pharmaceutical Executive Magazine

Member, Editorial Advisory Board

2020 - Present

Ernst & Young

Senior Advisor

2022 - Present

Indivior PLC

Audit, Science, Remuneration and Compensation, Nominating and Compliance Committees

2021 - Present

MiNK Therapeutics

Audit Committee (Chair) and Compensation Committees

2021 - Present

OcuTerra Therapeutics

Audit and Finance Committees

2022 - Present

Safecor Health

Audit and Compensation Committees

2022 - Present

Azitra

Audit and Compensation (Chair) Committees

2020 - Present

INVO Bioscience

Audit, Compensation, Nominating and Governance, and Finance (Chair) Committees

2020 - Present

The Biopharma Hub

Faculty Member

2018 - Present

Red Door Community New York

Member, Board Of Directors

2014 - Present

Springboard Enterprises

Life Sciences Council Member

2012 - Present

The Galien Foundation

Member, Executive Advisory Board For Prix Galien

2010 - Present

Fabulous Pharma Females 501 (c) (3)

FOUNDER

2010 - 2019

Villa Maria Education Center

Chair, Board Of Trustees

2008 - Present

Pharmaceutical Executive Magazine

Member, Editorial Advisory Board

Testimonials

Barbara Ryan is unmatched in her expertise in value creation, investor relations, capital raising, and communication. Barbara's profound insights into the industry, mastery of value creation strategies, and exceptional communication skills have been nothing short of transformative for our endeavors.

Our partnership included building and expanding our businesses, launching an IPO, and growing our partnerships. Barbara is not just a remarkable advisor; she stands as an exceptional individual and mentor who has been an invaluable contributor to our successes.

Jennifer S. Buell, PhD

President and CEO | MiNK Therapeutics

Chairman, Executive Council | agenus inc.

Barbara is an IR and communications expert who has a great network. She was instrumental in helping my prior company do a $100m+ capital raise. I would recommend her for companies who need a highly experienced consultant.

Ameet Mallik

CEO

ADC Therapeutics

Barbara has proven to be an exceptional asset to our Investor Relations team, enhancing our earnings materials with her meticulous attention to detail, strategic insights and clear communication skills. Her expertise and contributions have been invaluable in shaping transparent and impactful earnings communications that effectively resonate with our stakeholders.

Molly Cameron (she/her)

Director, Corporate Communications & Investor Relations

Marinus Pharmaceuticals

We selected Barbara Ryan as our IR representative because of her in-depth knowledge of the biotech industry. She has a tremendous reputation with sell side and buy side analysts, investment bankers and lawyers. Her positive communication style has helped create a trusting relationship with our investors. She has really become an integral part of our team.

Bill Conkling

Chief Executive Officer | Rafael Holdings Inc.

I’ve been fortunate to have Barbara as my friend and corporate communications strategist for the past 5 years. As a biotech CFO and board director I have always been able to count on her for insightful and unvarnished feedback on PRIR communications issues. Barbara has a network of biopharma colleagues developed over decades that is a huge asset and differentiates her from others in the business.

She is a pleasure to work with, has a tireless energy, and as a teammate I would recommend her highly.

Greg Weaver, CFO

Atossa Therapeutics

Barbara’s over forty years of biopharma experience as an analyst, consultant and within management enable deep insights and contributions across all areas of Board strategy and governance to help patients and create shareholder value.  Specifically,

she has helped optimize our acquisition of Opiant, investor relations strategy and communications, our Company strategy as well as an additional US listing on NASDAQ.   We are privileged to have her as a non-executive director.

Mark Crossley

CEO Indivior Inc

Over the past years, I have worked with Barbara in raising over $900 million of public and private investment that enabled Radius Health (RDUS) to go public and commercialize Tymlos and Eloxx Pharmaceuticals (ELOX) to uplist to NASDAQ and advance the Cystic Fibrosis Phase 2 program/pipeline.

Her well established network of senior relationships in the finance, media, and pharmaceutical industries enhanced our strategy, growth trajectory and enhanced our Board discussions. She is a well respected, consummate professional with the ability to deliver actionable insights in building biotechnology Companies.

Bob Ward

Experienced Startup CEO | Entrepreneur Innovator | Board Member | Board Chair | Audit Committee Chair | Creative Catalyst

I was introduced to Barbara through a mutual connection while I was with Gemini Consulting/Cap Gemini in the life sciences practice. I wanted to have Barbara speak to our pharmaceutical consultants to better help them understand the industry and their clients. Barbara was gracious enough to meet with our consultants and share her knowledge of the industry.

The people attending her presentation were amazed at her knowledge of the industry and insight into the driving forces that our clients were facing. Our consultants were themselves very bright and experienced, tasked with helping major pharmaceutical companies solve their business issues, but Barbara’s presentation, her insight into the industry, blew them away. She knows what drives the industry, where the problems are and where the opportunities are. If I had questions about the industry and needed advise, Barbara would be the first, last and most important conversation I would have.

Demand Marketing Director | Medidata Solutions

Media

Podcasts

Breaking glass ceilings with Barbara Ryan

Barbara Ryan lives in New York City. She started her corporate career working on Wall Street. In the late seventies. It's interesting to hear her talk about how much has evolved (and unfortunately how much has not) when it comes to ambitious females navigating their career trajectory over the last 4 decades in one of the worlds most cutthroat economies.

Ever Struggle With Being “The Only” in the Room?

Barbara Ryan, wall street pioneer and glass breaker, shares how she built an incredible career in the traditionally male dominated financial sector. Her practical advice about not just surviving but thriving in muddy career terrain is priceless. Today Barbara serves as a public company board member, editorial advisor for a pharmaceutical executive magazine, and founder of Fabulous Pharma Females.

Barbara Ryan on pharma and biotech boards

Today on the Take on Board podcast, I talk to Barbara Ryan about her journey to the boardroom. Barbara began her career on Wall Street as a sell side analyst covering the large-cap pharma industry for over 30 years. Following her career on the street. She founded her own capital market strategic advisory firm in 2013 and has led the investor relations and communication efforts for a variety of biopharma companies.

Entelechy Leadership Stories

Because of our interest in the topic of women in leadership, Barbara Ryan brought plenty of insights and experience to our conversation. Barbara founded Barbara Ryan Advisors, a capital markets and communications firm, following a more than 30-year career on Wall Street as a managing director in healthcare for Deutsche Bank. She is a longtime advocate for diversity & inclusion and is now a board director for two companies. Barbara understands that you have to do things differently when you are a woman.

Fabulous Pharma Females

Barbara Ryan, founder of Barbara Ryan Advisors, a member of PharmExec’s editorial advisory board, and the founder of Fabulous Pharma Females discusses the strong community she’s built providing women the opportunity to connect with each other and reinforce their shared commitment to one another.

Article

Barbara Ryan on Community— Fostering and Strengthening Relationships Among Veteran and Emerging Female Leaders

October 7, 2020

Barbara Ryan is the founder of Fabulous Pharma Females, a non-profit dedicated to the advancement of women in the biopharmaceutical industry. As a 35-plus-year veteran of the bio pharmaceutical industry, healthcare company Board Member and finance expert and C-suite advisor, she recognizes the power of investing in trusted relationships when it comes to achieving common

Competition for Biotech CFOs is Heating Up

May 20, 2020

Finding the right talent to fill leadership positions is never easy. But when the market is flooded with opportunities and the coveted qualifications are specialized, the task becomes a real issue. This is a current concern for many biotech companies looking to fill chief financial officer (CFO) positions. The recent biotech explosion combined with a desired candidate skill set that includes life sciences and capital markets experience has created a

Monthly Finance Column Pharmaceutical Executive Magazine

Are We Close to a Peak in Interest Rates?

October 11, 2023

"When you know it is coming—but it takes forever to get there."
Year to date, the S&P 500 is up an impressive 16% and near an all-time high (as of this writing). Growth continues to underperform. At the furthest end of the risk curve is biotech, with the XBI down about 8.5% on the year, only modestly off this year’s low and down 46% from the all-time highs set in October 2020 and early 2021.

No Rate Relief in Sight for Biotech

September 7, 2023

Retail sales, industrial production, and housing starts all came in above consensus expectations for the month of July. According to Michael Darda, chief economist and market strategist at Roth Capital Markets, “[S]trong data is at variance with the FOMC’s intention to impose a restrictive monetary stance and ‘hold there,’ such that growth moves below trend and inflation moves back to target. Any signs that growth is at, or above, trend will be met with tighter monetary policy than would otherwise prevail. We can see this most clearly in the 36-month Fed fund future, where the implied policy rate has risen more than 100 bps since the spring of this year. Market rates have risen in sympathy.”

More Evidence is Pointing to Potential Swing for Biotech

August 10, 2023

Biotech continues to significantly underperform the S&P500, which year to date is up 18.2% versus the XBI (up just 2.4%). The broader market recently resumed its upward trend as CPI data was a bit cooler than expected despite continued strong job growth. The debate on the overall market continues to be on the bullish side—a slowdown in rate hikes or plateau combined with the prospects for a soft landing and no recession. The bear case is that the Fed continues to

Shifting Macro Trends Offer Hope for Biotech Performance Boost

July 6, 2023

For the first time since January 2022, the Fed did not raise interest rates at its latest meeting, halting a streak of 10 straight previous hikes and putting at least a pause on the most rapid Fed-induced rise in interest rates in history. That is great news for rate-sensitive biotech stocks

Could a Rates Pivot By Fed Change Biotech’s Fate?

June 7, 2023

After peaking in early 2021 at more than $140, the biotech XBI index hit a low of about $74 in April 2022 and has bounced around ever since with little overall progress—one step forward followed by one step back. As of May 31, the XBI stands at about $84. This has been the steepest and longest bear market for the index since its inception.

Will Recent Surge in M&A Dealmaking Save Biotech Sector?

May 8, 2023

2023 started out with a fair amount of investor optimism that biotech would come out of its steepest and longest bear market since the inception of the XBI index in 2006 and see an acceleration in M&A. The M&A would certainly be fueled by the combination of a high level of innovation; record firepower of $1.4 billion across the largest acquirers, according to EY’s Annual Firepower Report; and looming LOEs on products representing a total of more than $300 billion in revenues, leaving a vacuous growth gap to fill in order to achieve growth targets

Does the Biotech Sector Have Reason to Be Optimistic?

April 11, 2023

The new year started with a fair amount of investor optimism that biotech would come out of its steepest and longest bear market since the inception of the XBI index in 2006. From its peak in early 2021, the XBI fell roughly 57% to a recent low of $63 in June 2022. By early February of this year, the biotech index had climbed its way back to $92, and investors found reasons to be optimistic. Some of those reasons include:

More than Ever, Data Will Dictate Future Fortunes

March 10, 2023

Last month I wrote about some emerging green shoots in the biotech sector, suggesting a potential recovery in 2023 performance following the steepest and longest decline in the sector in its history. These green shoots included data suggesting an easing in inflation—thus, potentially a more dovish Fed and an easing in rate hikes. These were coupled with rising expectations for a recession and ultimately declining rates. If these come to pass, investors would likely have rotated out of value and back into growth stocks, specifically biotech.

Data Signals Some Green Shoots for Biotech in 2023

February 9, 2023

Following epic capital inflows and stock market outperformance for the biotech sector in 2020, the XBI index subsequently had its steepest and longest decline from early 2021 through 2022. The XBI underperformed the S&P 500 in each of the past two years; something that has not happened since the inception of the index more than 15 years ago.

Biopharma Investment Implications: Looking Back and Forward

January 12, 2023

It’s Dec. 19, 2022, as I write this, and I can’t help but reflect on the past year. However, this column won’t get published until we are likely in the late innings of the J.P. Morgan Healthcare (JPM) Conference—many of us in person for the first time since January 2020, which is hard to believe.

Back in Person, Sparks Could Fly at Upcoming J.P. Morgan Conference

December 8, 2022

In January 2020, healthcare industry movers and shakers descended on San Francisco for the 38th Annual J.P. Morgan Healthcare Conference, the definitive Woodstock of healthcare. Who could have imagined that we would not return until January 2023. What will we be talking about?

The New Reality for Industry Dealmaking May be Setting In

November 9, 2022

A near-record number of emerging biotech companies are trading at negative enterprise values and by year end, if nothing changes, nearly 40% will have less than 12 months of cash.This is despite the fact that in 2021, emerging biotechs raised more than $80 billion in follow-on financing, venture funding, and initial public offerings (IPOs), second only to the record amount of $90 billion raised in 2020.

All About the Rates: The Fallout of Fed Hikes for Biotech

October 12, 2022

Rising interest rates are the enemy of long-dated assets as they put heavy downward pressure on valuations. As biotech is likely the longest dated of all asset classes, its valuations will run in an inverse direction to interest rates, which can explain part of the longest and steepest decline in the XBI since its inception.

The Biotech Rally Continues—What’s Fueling the Surge?

September 9, 2022

The decline in biotech was in large part driven by the reopening of the economy, as investors fled growth stocks in favor of the now very cheap cyclicals left for dead during the shutdown. This began the correction in the biotech sector.

Has Biotech Bottomed Out—and is Recent Recovery Sustainable?

August 10, 2022

In our June column, we speculated about whether the XBI biotech index could be close to a bottom following the longest and steepest decline since its inception. On May 11, the XBI traded as low as $62.81, a level it essentially retested one month later on June 14. From its peak in February 2021 to this recent trough, the index has been in decline for 16 months and fallen nearly 62%.

Biotech Performance Glance—and Promising Ripples for Recovery

July 8, 2022

My colleagues at Ernst & Young LLP (EY US) recently published “Beyond Borders: EY biotechnology report 2022,” providing a snapshot of the current state of the industry and its strong fundamentals. I am pleased to share their key findings here.

Are We Closer Than Ever to a Biotech Bottom?

June 9, 2022

As we live through the steepest and longest bear market in biotech history, historical precedents offer little value in assessing how much lower we could fall or for how long. According to a recent biotech market update from Tim Opler and team at Torreya, over one-third of biotechs have lost 75% of their value since the market peaked in early 2021, over 200 companies are trading below enterprise value, and two-thirds of biotechs have an enterprise value below $100 million (vs. 36% in November 2021).

Biotech Prospects for Stayin’ Alive During Correction

May 11, 2022

The pace of biotech company restructurings has become so brisk that Fierce Biotech is now publishing a Layoff Tracker to keep up. While the XBI (biotech) index is down 45% from its highs in early 2021, that does not begin to tell the story for many earlystage biotechs who went public during the heady capital markets of 2021 and 2020. For many in this class, stock prices are down 80% to 90%, and there are currently over 150 companies in the sector now trading below cash.

Surviving Biotech’s Longest and Steepest Bear Market Ever

April 11, 2022

Nothing in life is a sure thing. But investing in biotech, and biotech IPOs in 2020 specifically, seemed as close as you could get. In fact, the returns were so consistently outsized, investment managers competing for returns could not afford to not aggressively participate.

Biopharma Stocks, M&A Sputter Amid More Headwinds

March 8, 2022

Inflation reports continue to worsen. We reached 7.5% year over year in the US in January, the highest level in 40 years. This suggests the Fed will be busy raising rates to a greater extent and for a longer period of time than previously thought.

What’s Up in Biotech These Days? Not Much, Unfortunately

February 9, 2022

Fundamentals in the biopharma industry generally are healthy, with the leading companies continuing to report sales and earnings ahead of expectations and raising forward guidance. That said, the sector’s performance continues to lag the market. The large cap pharma DRG index was up a historically very strong 18.7%, largely owing to a 60.4% gain in Pfizer, which of course was fueled by expected sales of $36-plus billion for 2021 and likely another $30 billion in 2022—an unprecedented windfall.

Biopharma Reaches New Heights as Calendar Turns

January 12, 2022

A decade ago, my colleagues at EY (where I am a senior advisor) created the Firepower Index to understand a company’s total capacity to fund deals to achieve their growth goals. EY defines Firepower by the strength of a company’s balance sheet and market capitalization.

Could 2022 Prove to Be Better Year for Biotech Companies?

November 9, 2021

Large pharma—and just about everything else, literally—has outperformed biotech in 2021. Yet, investors still poured record sums of money into the sector in the form of new VC, and subsequent dollars backing IPOs, SPACs, and follow-on offerings. 2020 saw a record number of IPOs in biotech, 69 in total, and the class saw an average stock price appreciation of 38%, substantially outperforming the market.

JPM Conference Goes Virtual: What Will it Mean?

January 8, 2021

Normally this month, 12,000 participants in the healthcare industry (senior management, bankers, investors, analysts, etc.) converge in San Francisco for the annual J.P. Morgan Healthcare Conference.As was the case with Woodstock, all the “players” are there and they go at it day and night, but not this year

For Investors, ’Tis the Season to be Grateful

December 11, 2020

In the month of November, the biotech sector had its biggest run up since the Spring. Perhaps optimism for a COVID-19 vaccine, a shining example of our industry’s innovative prowess and critical importance of its contributions. In the last 25 years, there have been seven novel vaccines developed; four of these came from Merck

A Record Year, But Will Recent Valuation Fatigue Continue?

November 16, 2020

Who would have predicted back in early March as we went into a COVID-induced lockdown, that the biopharma sector would see a fierce record streak of financings?

The SPAC Makes a Comeback!

October 14, 2020

The special purpose acquisition company (SPAC), or “blank-check company,” originally introduced decades ago as a cleaner form of a reverse merger shell, has made an impressive comeback. A SPAC has one purpose: to merge with a company and take it public (“de-SPAC”). Typically, when a biotech company does an IPO, it raises cash to fund the development of its assets.

Biopharma Capital Markets Sizzle in 2020

September 11, 2020

Impressively, about 90% of them were upsize, with an average increase in the number of shares issued of around 30%, and 85% of these deals priced at the high end or above the range. The average return for biotech IPOs year to date exceeds 80%. Since money truly does chase returns, it is not surprising that the sector has generated the largest levels of oversubscription.

Leaders Need to Hit Pricing Issue Head-On

August 10, 2020

It’s hard to imagine legislation enacting any of the measures by Nov. 7; the executive orders are likely only symbolic as they are notoriously limited, can be challenged in court, and include no details on implementation or timing. Nevertheless, the effort and rhetoric are worthy of inspection.

Will COVID-19 Usher in a New Era in Pharma Marketing?

July 22, 2020

As COVID-19 takes the global healthcare ecosystem hostage, biopharma companies, healthcare providers (HCPs), and patients have been forced into new models of accessing care. Brick and mortar visits are being supplemented by digital tactics and a reluctance to adopt telemedicine has been replaced by the necessity to do so

Will the Biopharma Leaders Please Take the Stage!

June 12, 2020

Over the past month, and year to date, biotech stocks have massively outperformed the markets, financings are on a tear, money continues to pour into the space, and M&A is alive and well. The Nasdaq Biotech ETF is currently trading above its late 2019 and early

Biotech in the Age of COVID: The Pain and the Gain

May 13, 2020

When I discussed writing a monthly finance column for Pharmaceutical Executive with Editorial Director Lisa Henderson a few months ago, I never imagined that my first installment would focus on a once-in-a-100-year storm. COVID-19 dominates all things around the globe, including normally recession-resilient biotech.